Key result
The RE-VERSE AD trial is a global phase 3 prospective cohort study designed to investigate idarucizumab in dabigatran-treated patients with severe bleeding or requiring urgent surgery.
Cohort
Yes
Answers are grounded in this paper and cite their sources.
Establishes dedicated reversal for dabigatran emergencies; extends targeted antidote options beyond nonspecific agents.
Idarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERSal Effects of Idarucizumab in Patients on Active Dabigatran (RE-VERSE AD™) is a global phase 3 prospective cohort study aimed at investigating idarucizumab in dabigatran-treated patients who present with uncontrollable or life-threatening bleeding, and in those requiring urgent surgery or intervention. We describe the rationale for, and design of the trial (clinicaltrials.gov NCT02104947).
No takes yet. Share an insight, caveat, or question.
Reilly et al. (2015) conducted a cohort in Dabigatran-treated patients with uncontrollable or life-threatening bleeding, or requiring urgent surgery or intervention. Idarucizumab was evaluated. The RE-VERSE AD trial is a global phase 3 prospective cohort study designed to investigate idarucizumab in dabigatran-treated patients with severe bleeding or requiring urgent surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: